Litigation Details for UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC. (D.N.J. 2015)
✉ Email this page to a colleague
UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC. (D.N.J. 2015)
| Docket | ⤷ Subscribe | Date Filed | 2015-07-22 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-09-18 |
| Cause | 35:271 Patent Infringement | Assigned To | Peter G. Sheridan |
| Jury Demand | None | Referred To | Lois H. Goodman |
| Parties | WATSON LABORATORIES, INC. | ||
| Patents | 6,521,212; 6,756,033; 8,497,393; 9,339,507; 9,358,240 | ||
| Attorneys | JOSEPH L. LINARES; LIZA M. WALSH | ||
| Firms | McCarter and English, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe , ⤷ Subscribe , and ⤷ Subscribe .
Details for UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC. (D.N.J. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-07-27 | 130 | Hatch-Waxman patent case involving five patents: U.S. Patent Nos. 6,521,212 (“the ’212 patent”), 6,756,033…,033 (“the ’033 patent”), 8,497,393 (“the ’393 patent”), 9,339,507 (“the ’507 patent”), and 9,358,240… the patents-in-suit, the ‘393 patent, was determined to be invalid by the United States Patent and Trial…2017. Two additional patents-in-suit, the ‘507 and ‘240 patents, are currently the subject of…resolution of two recently-filed IPRs on two of the patents-in-suit. If the stipulation and proposed order | External link to document | |
| 2018-01-15 | 137 | Hatch-Waxman patent case involving five patents: U.S. Patent Nos. 6,521,212 (“the ’212 patent”), 6,756,033…,033 (“the ’033 patent”), 8,497,393 (“the ’393 patent”), 9,339,507 (“the ’507 patent”), and 9,358,240… the patents-in-suit, the ‘393 patent, was determined to be invalid by the United States Patent and Trial…certiorari. Two additional patents-in-suit, the ‘507 and ‘240 patents, are currently the subject of… 2019. The final two patents-in-suit, the ‘212 and ‘033 patents, are set to expire on November | External link to document | |
| 2016-06-21 | 49 | seq., involving United States Patent Nos. 6,521,212 (“the ’212 patent”) (attached as Exhibit A hereto…of the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and the ’240 patent, inclusive…the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and/or the ’240 patent, including…of the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and the ’240 patent, inclusive…the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and/or the ’240 patent prior to | External link to document | |
| 2016-08-05 | 54 | Correct INFRINGEMENT CONTENTIONS FOR U.S. PATENT NO. 8,497,393 by UNITED THERAPEUTICS CORPORATION. (Attachments… 18 September 2018 3:15-cv-05723 830 Patent None District Court, D. New Jersey | External link to document | |
| 2016-08-05 | 55 | Correct INFRINGEMENT CONTENTIONS FOR U.S. PATENT NO. 8,497,393 (Attachments: # 1 Declaration of ROBERT … 18 September 2018 3:15-cv-05723 830 Patent None District Court, D. New Jersey | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
